Report cover image

Global Hospital Acquired Infections Diagnostics Market Size Study, by Test (Molecular, Conventional), by Infection (UTI, Pneumonia), by Product (Consumables, Instruments), by Type (Blood Tests, Urinalysis), and Regional Forecasts 2024-2034

Publisher Factview Research
Published Oct 03, 2025
Length 285 Pages
SKU # FAVR20464151

Description

The global hospital-acquired infections (HAI) diagnostics market was valued at approximately USD 4.29 billion in 2024 and is anticipated to expand at a CAGR of 1.6% over the forecast period 2025-2034. The alarming rise in the prevalence of HAIs, including surgical site infections, bloodstream infections, ventilator-associated pneumonia, and catheter-associated urinary tract infections, has propelled the demand for rapid and accurate diagnostic solutions. Hospitals, diagnostic laboratories, and healthcare facilities worldwide are increasingly adopting advanced molecular testing methods to curb infection outbreaks and improve patient safety.

The demand for early detection and effective containment of HAIs has intensified, given their impact on hospital mortality rates, prolonged hospital stays, and rising treatment costs. According to the World Health Organization (WHO), nearly 1 in 10 hospitalized patients worldwide is likely to contract an HAI, while the Centers for Disease Control and Prevention (CDC) states that 1 in 31 hospitalized patients in the U.S. acquires an HAI daily. The economic burden associated with HAIs, exceeding USD 28 billion annually in the U.S. alone, further underscores the need for advanced diagnostic tools. The growing threat of multidrug-resistant organisms (MDROs), including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile (C. difficile), is driving the adoption of molecular diagnostics such as Polymerase Chain Reaction (PCR)-based tests, enabling early detection and effective treatment strategies.

The conventional diagnostic methods segment held a dominant share of the market in 2024, owing to their established reliability and affordability. However, molecular diagnostics, with its ability to offer rapid pathogen detection, is expected to witness the fastest CAGR of 1.71% during the forecast period. Technological advancements such as real-time PCR, multiplex PCR, and next-generation sequencing (NGS) have significantly enhanced diagnostic accuracy and turnaround times, aiding infection control measures in hospitals and intensive care units (ICUs). For instance, in April 2024, Llusern Scientific introduced the Lodestar DX analyzer for rapid urinary tract infection (UTI) diagnostics, emphasizing the growing shift toward advanced molecular detection techniques.

Geographically, Europe dominated the global market in 2024, capturing the largest share due to stringent hospital infection control policies, extensive healthcare expenditure, and the presence of leading diagnostic manufacturers such as bioMérieux and QIAGEN. The Asia-Pacific region is projected to exhibit the fastest growth rate, driven by increasing awareness, rising healthcare investments, and an expanding geriatric population more susceptible to HAIs. Countries like China and India are implementing government-led infection monitoring programs to strengthen HIV, tuberculosis, and antibiotic resistance control measures, further driving market growth. Meanwhile, North America remains a strong contender, given its high prevalence of HAIs, well-established healthcare infrastructure, and ongoing R&D efforts in automated molecular diagnostic systems.

Major market players included in this report are:
  • Abbott
  • bioMérieux S.A.
  • Hoffmann-La Roche Ltd.
  • Siemens Healthcare Private Limited
  • Becton, Dickinson and Company (BD)
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Meridian Bioscience, Inc.
  • Hologic, Inc.
  • Cepheid (Danaher Corporation)
  • Bio-Rad Laboratories, Inc.
  • Luminex Corporation
  • GenePOC Inc.
  • T2 Biosystems, Inc.
  • Accelerate Diagnostics, Inc.
The detailed segments and sub-segments of the market are explained below:

By Test:
  • Molecular
  • Conventional
By Infection:
  • Urinary Tract Infection (UTI)
  • Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Others
By Product:
  • Consumables
  • Instruments
By Type:
  • Blood Tests
  • Urinalysis
By Region:

North America
  • U.S.
  • Canada
Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
Latin America
  • Brazil
  • Argentina
Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Years considered for the study are as follows:
  • Historical Year – 2022
  • Base Year – 2024
  • Forecast Period – 2024 to 2034
Key Takeaways:
  • Market estimates & forecasts from 2022 to 2034.
  • Detailed regional and segmental analysis.
  • Competitive landscape with insights into key players and strategic developments.
  • Investment opportunities, technological advancements, and regulatory frameworks shaping the industry.
  • Analysis of market demand-supply dynamics and consumer behavior trends.

Table of Contents

285 Pages
Chapter 1. Global Hospital Acquired Infections Diagnostics Market Executive Summary
1.1. Global Hospital Acquired Infections Diagnostics Market Size & Forecast (2024-2034)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Test
1.3.2. By Infection
1.3.3. By Product
1.3.4. By Type
1.4. Key Market Trends
1.5. Recession Impact
1.6. Industry Metrics
1.7. Investment Analysis
1.8 .Investment Rationale
1.9. Analyst Recommendation & Conclusion
Chapter 2. Global Hospital Acquired Infections Diagnostics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Hospital Acquired Infections Diagnostics Market Dynamics
3.1. Market Drivers
3.1.1. Increasing prevalence of HAIs and antimicrobial resistance
3.1.2. Advancements in molecular diagnostic technologies
3.1.3. Growing hospital infection control initiatives
3.2. Market Challenges
3.2.1. High costs associated with advanced diagnostic systems
3.2.2. Stringent regulatory approval processes
3.3. Market Opportunities
3.3.1. Emerging AI-powered diagnostic solutions
3.3.2. Expansion of healthcare infrastructure in developing economies
3.3.3. Increasing investments in R&D for rapid testing methods
Chapter 4. Global Hospital Acquired Infections Diagnostics Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s Five Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Test (2024-2034)
5.1. Segment Dashboard
5.2. Global Market: Test Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Molecular Diagnostics
5.2.2. Conventional Diagnostics
Chapter 6. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Infection (2024-2034)
6.1. Segment Dashboard
6.2. Global Market: Infection Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.2.1. Urinary Tract Infection (UTI)
6.2.2. Pneumonia
6.2.3. Surgical Site Infections
6.2.4. Bloodstream Infections
6.2.5. Others
Chapter 7. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Product (2024-2034)
7.1. Segment Dashboard
7.2. Global Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.2.1. Consumables
7.2.2. Instruments
Chapter 8. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Type (2024-2034)
8.1. Segment Dashboard
8.2. Global Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
8.2.1. Blood Tests
8.2.2. Urinalysis
Chapter 9. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Region (2024-2034)
9.1. North America Hospital Acquired Infections Diagnostics Market
9.1.1. U.S.
9.1.1.1. Test breakdown size & forecasts, 2022-2032
9.1.1.2. Infection breakdown size & forecasts, 2022-2032
9.1.1.3. Product breakdown size & forecasts, 2022-2032
9.1.1.4. Type breakdown size & forecasts, 2022-2032
9.1.2. Canada
9.2. Europe Hospital Acquired Infections Diagnostics Market
9.2.1. U.K.
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia-Pacific Hospital Acquired Infections Diagnostics Market
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America Hospital Acquired Infections Diagnostics Market
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa Hospital Acquired Infections Diagnostics Market
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Abbott
10.1.2. bioMérieux S.A.
10.1.3. Hoffmann-La Roche Ltd.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Abbott
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. bioMérieux S.A.
10.3.3. Hoffmann-La Roche Ltd.
10.3.4. Siemens Healthcare Private Limited
10.3.5. Becton, Dickinson and Company (BD)
10.3.6. QIAGEN
10.3.7. Thermo Fisher Scientific Inc.
10.3.8. Meridian Bioscience, Inc.
10.3.9. Hologic, Inc.
10.3.10. Cepheid (Danaher Corporation)
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us